Sarepta Therapeutics (SRPT) Tops Q4 EPS by 23c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.24), $0.23 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $258.4 million versus the consensus estimate of $250.4 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight